Home Featured Page 55

Featured

Latest

Pα+ February 2026 Psychedelic Bill Roundup

Navigating Colorado’s Regulated Psychedelic Model: Lessons From the Front Lines

The State of the Psychedelic Industry & Open Questions (Video)

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin, DMT, and Methylone Studies; RAND Polling Reveals 23% of Americans Support Legal Psilocybin...

Navigating Psychedelics for Clinicians and Wellness Practitioners: LIVE

What is Holding Space: Guiding Psychedelic Journeys and Creating Ideal Set...

Preserving Psychedelic Legacies: Shulgin Farm and the Shulgin Archive Project

Natural Medicine Advisory Bulletin 10.1: Legislative Update

MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around...

Women and Psychedelics, Microdosing, and the Challenges of Psychedelic Parenthood

Natural Medicine Advisory Bulletin 10: March 2024

Senator Kirk Cullimore on Utah’s MDMA and Psilocybin Pilot Program

The Alexander Shulgin Research Institute and the Future of Psychedelic Drug...

EDITOR PICKS

Pα+ February 2026 Psychedelic Bill Roundup

Navigating Colorado’s Regulated Psychedelic Model: Lessons From the Front Lines

The State of the Psychedelic Industry & Open Questions (Video)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ February 2026 Psychedelic Bill Roundup

Navigating Colorado’s Regulated Psychedelic Model: Lessons From the Front Lines

The State of the Psychedelic Industry & Open Questions (Video)

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin, DMT, and Methylone Studies; RAND Polling Reveals 23% of Americans Support Legal Psilocybin...

Navigating Psychedelics for Clinicians and Wellness Practitioners: LIVE

What is Holding Space: Guiding Psychedelic Journeys and Creating Ideal Set...

Preserving Psychedelic Legacies: Shulgin Farm and the Shulgin Archive Project

Natural Medicine Advisory Bulletin 10.1: Legislative Update

MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around...

Women and Psychedelics, Microdosing, and the Challenges of Psychedelic Parenthood

Natural Medicine Advisory Bulletin 10: March 2024

Is Cannabis a Psychedelic?

Senator Kirk Cullimore on Utah’s MDMA and Psilocybin Pilot Program

The Alexander Shulgin Research Institute and the Future of Psychedelic Drug...

EDITOR PICKS

Pα+ February 2026 Psychedelic Bill Roundup

Navigating Colorado’s Regulated Psychedelic Model: Lessons From the Front Lines

The State of the Psychedelic Industry & Open Questions (Video)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY